Literature DB >> 19586083

Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs.

Brian Godman, Ulrich Schwabe, Gisbert Selke, Björn Wettermark.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19586083     DOI： 10.2165/00019053-200927050-00010

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  17 in total

1.  Pharmaceutical regulation in France 1980-2003.

Authors:  Valérie Paris
Journal:  Int J Health Plann Manage       Date:  2005 Oct-Dec

2.  Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?

Authors:  Reinhard Busse; Jonas Schreyögg; Klaus-Dirk Henke
Journal:  Int J Health Plann Manage       Date:  2005 Oct-Dec

3.  Balancing Big Pharma's books.

Authors:  Andrew Jack
Journal:  BMJ       Date:  2008-02-23

Review 4.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 5.  Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance.

Authors:  Brian Godman; Björn Wettermark; Mikael Hoffmann; Karolina Andersson; Alan Haycox; Lars L Gustafsson
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2009-02       Impact factor: 2.217

6.  Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?

Authors:  B Greg Brown; Allen J Taylor
Journal:  N Engl J Med       Date:  2008-03-30       Impact factor: 91.245

7.  Trends in generic prescribing and dispensing in Europe.

Authors:  Steven Simoens
Journal:  Expert Rev Clin Pharmacol       Date:  2008-07       Impact factor: 5.045

8.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

Authors:  Anne B Rossebø; Terje R Pedersen; Kurt Boman; Philippe Brudi; John B Chambers; Kenneth Egstrup; Eva Gerdts; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph A Nienaber; Simon Ray; Terje Skjaerpe; Kristian Wachtell; Ronnie Willenheimer
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

9.  Analyses of cancer data from three ezetimibe trials.

Authors:  Richard Peto; Jonathan Emberson; Martin Landray; Colin Baigent; Rory Collins; Robert Clare; Robert Califf
Journal:  N Engl J Med       Date:  2008-09-02       Impact factor: 91.245

10.  Simvastatin with or without ezetimibe in familial hypercholesterolemia.

Authors:  John J P Kastelein; Fatima Akdim; Erik S G Stroes; Aeilko H Zwinderman; Michiel L Bots; Anton F H Stalenhoef; Frank L J Visseren; Eric J G Sijbrands; Mieke D Trip; Evan A Stein; Daniel Gaudet; Raphael Duivenvoorden; Enrico P Veltri; A David Marais; Eric de Groot
Journal:  N Engl J Med       Date:  2008-03-30       Impact factor: 91.245
View more
  9 in total

Review 1.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

Authors:  Jakub Adamski; Brian Godman; Gabriella Ofierska-Sujkowska; Bogusława Osińska; Harald Herholz; Kamila Wendykowska; Ott Laius; Saira Jan; Catherine Sermet; Corrine Zara; Marija Kalaba; Roland Gustafsson; Kristina Garuolienè; Alan Haycox; Silvio Garattini; Lars L Gustafsson
Journal:  BMC Health Serv Res       Date:  2010-06-07       Impact factor: 2.655

2.  Policies to enhance prescribing efficiency in europe: findings and future implications.

Authors:  Brian Godman; William Shrank; Morten Andersen; Christian Berg; Iain Bishop; Thomas Burkhardt; Kristina Garuoliene; Harald Herholz; Roberta Joppi; Marija Kalaba; Ott Laius; Julie Lonsdale; Rickard E Malmström; Jaana E Martikainen; Vita Samaluk; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; Lesley Tilson; F Cankat Tulunay; Vera Vlahović-Palčevski; Kamila Wendykowska; Bjorn Wettermark; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2011-01-07       Impact factor: 5.810

Review 3.  Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.

Authors:  Brian Godman; Bjorn Wettermark; Menno van Woerkom; Jessica Fraeyman; Samantha Alvarez-Madrazo; Christian Berg; Iain Bishop; Anna Bucsics; Stephen Campbell; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Harald Herholz; Marija Kalaba; Ott Laius; Jutta Piessnegger; Catherine Sermet; Ulrich Schwabe; Vera V Vlahović-Palčevski; Vanda Markovic-Pekovic; Luka Vončina; Kamila Malinowska; Corinne Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2014-06-17       Impact factor: 5.810

4.  Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications.

Authors:  Brian Godman; Max Petzold; Kathleen Bennett; Marion Bennie; Anna Bucsics; Alexander E Finlayson; Andrew Martin; Marie Persson; Jutta Piessnegger; Emanuel Raschi; Steven Simoens; Corinne Zara; Corrado Barbui
Journal:  BMC Med       Date:  2014-06-13       Impact factor: 8.775

Review 5.  Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Authors:  Brian Godman; William Shrank; Bjorn Wettermark; Morten Andersen; Iain Bishop; Thomas Burkhardt; Kristina Garuolienè; Marija Kalaba; Ott Laius; Roberta Joppi; Catherine Sermet; Ulrich Schwabe; Inês Teixeira; F Cankat Tulunay; Kamila Wendykowska; Corinne Zara; Lars L Gustafsson
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-05

6.  Evaluation of statin utilization in the Republic of Macedonia during 2013-2016.

Authors:  Zorica Naumovska; Aleksandra K Nestorovska; Aleksandra Grozdanova; Kristina Hristova; Aleksandar Dimovski; Ljubica Suturkova; Zoran Sterjev
Journal:  Clinicoecon Outcomes Res       Date:  2018-06-26

7.  Potential to enhance the prescribing of generic drugs in patients with mental health problems in austria; implications for the future.

Authors:  Brian Godman; Anna Bucsics; Thomas Burkhardt; Jutta Piessnegger; Manuela Schmitzer; Corrado Barbui; Emanuel Raschi; Marion Bennie; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-01-07       Impact factor: 5.810

8.  Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs.

Authors:  Rickard E Malmström; Brian B Godman; Eduard Diogene; Christoph Baumgärtel; Marion Bennie; Iain Bishop; Anna Brzezinska; Anna Bucsics; Stephen Campbell; Alessandra Ferrario; Alexander E Finlayson; Jurij Fürst; Kristina Garuoliene; Miguel Gomes; Iñaki Gutiérrez-Ibarluzea; Alan Haycox; Krystyna Hviding; Harald Herholz; Mikael Hoffmann; Saira Jan; Jan Jones; Roberta Joppi; Marija Kalaba; Christina Kvalheim; Ott Laius; Irene Langner; Julie Lonsdale; Sven-Äke Lööv; Kamila Malinowska; Laura McCullagh; Ken Paterson; Vanda Markovic-Pekovic; Andrew Martin; Jutta Piessnegger; Gisbert Selke; Catherine Sermet; Steven Simoens; Cankat Tulunay; Dominik Tomek; Luka Vončina; Vera Vlahovic-Palcevski; Janet Wale; Michael Wilcock; Magdalena Wladysiuk; Menno van Woerkom; Corrine Zara; Lars L Gustafsson
Journal:  Front Pharmacol       Date:  2013-05-14       Impact factor: 5.810

Review 9.  The Assessment for Disinvestment of Intramuscular Interferon Beta for Relapsing-Remitting Multiple Sclerosis in Brazil.

Authors:  Livia Lovato Pires de Lemos; Augusto Afonso Guerra Júnior; Marisa Santos; Carlos Magliano; Isabela Diniz; Kathiaja Souza; Ramon Gonçalves Pereira; Juliana Alvares; Brian Godman; Marion Bennie; Ivan Ricardo Zimmermann; Vânia Crisitna Canuto Dos Santos; Clarice Alegre Pretramale; Francisco de Assis Acurcio
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.